Industry Briefs: August 27, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: August 27, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Research has opened a new cGMP spray-drying facility for high-potency drugs in Bend, Oregon. Read More

Bristol-Myers Squibb (BMS) has discontinued the development of BMS-986094, an investigational nucleotide polymerase inhibitor for treating hepatitis C. Read More

Claris Lifesciences has announced that it has ended its supply agreement with Pfizer. Read More

FDA has approved Gilead’s Stribild, a once-daily, single tablet regimen for treating HIV. Read More

Sanofi’s subsidiary Genzyme has received a Refuse to File letter from FDA for its biologics license application for Lemtrada (alemtuzumab), a monoclonal antibody to treat relapsing multiple sclerosis. The agency requested that the company modify the presentation of the data sets to enable the agency to better navigate the application. Read More

Synergy Pharmaceuticals has acquired FV-100, an orally available nucleoside analogue for treating shingles, from BMS. Read More

West Pharmaceutical India Packaging, an indirect subsidiary of West Pharmaceutical Services, has begun construction of its new compression molding facility in Sri City, India. The plant will become part of West’s global supply chain for its pharmaceutical packaging operations. Read More

The Wistar Institute of Philadelphia has signed a three-year collaborative agreement with DavosPharma to develop novel therapeutics. Read More

WuXi PharmaTech has agreed with TaiMed Biologics to manufacture Ibalizumab (TMB-355) in support of Phase II and III clinical trials. Read More

People Notes

DPT Laboratories has named Gene Ciolfi vice-president and general manager of the company’s Center Excellence for Sterile and Specialty Products. Read More

Hovione has appointed Conrad Winters as the company’s drug product development director. Read More

Roche has appointed Daniel O’Day as the head of Roche Pharma, effective Sept. 1, 2012. Roland Diggelmann will assume the position head of Roche diagnostics. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here